ResearchInhibition of MCL-1 and MEK overcomes MEK inhibitor resistance in triple-negative and inflammatory breast cancers
ResearchIncidence and risk factors for pneumonitis due to trastuzumab deruxtecan in metastatic breast cancer: a retrospective cohort study
ResearchSickle cell disease induces chromatin introversion and ferroptosis in CD8+ T cells to suppress anti-tumor immunity
ResearchDevelopment of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs
ResearchCase Report: Successful delivery following chemotherapy in a pregnant patient with metastatic SMARCB1-deficient renal medullary carcinoma
ResearchA phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer
ResearchIncidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: a retrospective cohort study
ResearchPhase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC
ResearchAdditional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity
ResearchComprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes
ResearchMaintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
ResearchPhase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"